BioMarin to Attend Three Upcoming Investor Conferences in March
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St futures flat after tech rout; Iran tensions, retail earnings in focus
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Target raises full-year sales forecast amid ongoing turnaround drive
- Global bond rout pauses as sovereign yields back off multi-decade highs
- Lowe's slashes full-year sales outlook amid DIY spending pressure
- Tech selloff weighs down Wall Street as bond yields climb
- Marvell issues Google warrant tied to custom chip deal
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Baird Assumes, Upgrades BioMarin (BMRN) to Outperform
March 7, 2016 4:06 PM ESTBaird assumes coverage and upgraded BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from Neutral to Outperform with a price target of $110.00 (from $100.00).
Analyst Michael Ulz commented, "We are assuming coverage and upgrading to an Outperform rating with a price target of $110. BioMarin... More
Wedbush Raises Price Target on BioMarin Pharma (BMRN) to $108 Following Promising BMN-190 Results
March 3, 2016 2:16 PM ESTWedbush reiterated a Neutral rating on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), and raised the price target to $108.00 (from $105.00), following the company's results from Phase 1/2 trial of BMN-190 for late infantile Batten disease. The results for BMN-190 demonstrated disease stabilization, and could be on the market in... More
